Despite the promising drug development news, the CEO signaled last month that she was willing to let public investors get hosed, with a low ball take-private offer of $0.40/share. I believe this pissed both public investors and the board members off. I'm not sure if the positive phase 2 results were icing on the cake.
Quite honestly this company is a ripe target for acquisition by a biopharma company like GSK or Roche.
My comment you replied to was attempting to communicate that, because the CEO holds most of the control over the company, it is preferable to let it slip into bankruptcy (where equity and their control will be wiped out) vs continuing allowing them the control they have, which is not leading to a favorable outcome for the enterprise. This is potentially superior to recapitalizing the existing enterprise and continuing to allow the CEO to light capital on fire.
[1] https://investors.23andme.com/news-releases/news-release-det... (draw your attention to quarterly burn rate and cash on hand)
[2] https://finance.yahoo.com/quote/ME/
[3] https://www.bloomberg.com/news/articles/2024-05-10/strugglin... |https://archive.today/yTo01
Edit: https://finance.yahoo.com/news/23andme-ceo-wojcicki-open-thi...
> A special committee formed by the company rejected Wojcicki's previous proposal, deeming it insufficient and not in the best interest of the non-affiliated shareholders.
I think we are disappointed that the market is giving $ME and many other companies non-ZIRP valuations at 95% discounts, and we don't have the cash to buy them at the bottom, like she can.
But having working science does not make a successful business plan.